KCKaiwen Chen

Kaiwen Chen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Kaiwen Chen has a total of 77 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Microvascular decompression compared with other surgical interventions for trigeminal neuralgia: A systematic review and meta-analysis

    by Shaun A. Nguyen, Kaiwen Chen, Cali Loblundo, Jacqueline P. Nguyen, Warren Chun, Sunil Patel, Matthew O. Herbst, Robert F. Labadie

    Microvascular decompression (MVD) is often considered the standard of care operation for medically refractory primary trigeminal neuralgia (PTN), yet there is variable evidence comparing its effectiveness with other procedures such as percutaneous balloon compression (PBC) or stereotactic radiosurgery (SRS). Following PRISMA guidelines, we systematically searched CINAHL, Cochrane Library, Embase, PubMed, and Scopus from inception through April 1, 2026. Studies of surgically naïve PTN patients undergoing procedural and surgical interventions for PTN comparing MVD with at least one other procedural or surgical intervention were included. Outcomes focused on pain relief, recurrence, repeat procedures, and complications. A total of 26 studies (7 prospective, including two randomized controlled trials, and 19 retrospective) comprising 3,806 patients were included. Across predominantly retrospective cohorts, MVD was associated with higher short‑term and long‑term pain relief and lower crude recurrence and reoperation rates than SRS (e.g., short‑term 94.7% vs. 67.3%; long‑term 79.4% vs. 55.4%; recurrence 9.5% vs. 32.0%). Versus RFR, MVD showed higher short‑term (89.0% vs. 68.5%) and long‑term pain relief (72.1% vs. 54.7%), with lower crude recurrence (20.7% vs. 38.3%) and fewer repeat procedures (10.7% vs. 53.5%). MVD and PBC demonstrated similar short‑term (89.3% vs. 91.8%) and long‑term relief (83.9% vs. 79.7%), whereas crude recurrence rates favored MVD (11.1% vs. 18.3%). Limited data suggested higher long‑term pain relief with MVD versus partial sensory rhizotomy (88.9% vs. 70.9%). MVD generally showed lower rates of persistent sensory complications than ablative or radiosurgical procedures. These patterns arise largely from nonrandomized studies with baseline imbalances and variable follow‑up. Recurrence and long‑term estimates are crude proportions without time‑to‑event adjustment and are therefore exploratory and descriptive. This systematic review and meta-analysis suggests that MVD is an important option for appropriately selected PTN patients, with observational comparative data showing higher crude long‑term pain relief, lower crude recurrence, and fewer persistent sensory complications than several alternatives. Given the predominance of retrospective, nonrandomized cohorts and heterogeneous follow‑up, the pooled recurrence and long‑term estimates are exploratory descriptive findings and cannot establish comparative durability or superiority of MVD over alternative interventions.

  • Open Access

    Republication de : Sex and survival in oropharyngeal squamous cell carcinoma: A systematic review and meta-analysis

    by W.B. Chun, E.S. Chernov, K. Chen, S.A. Nguyen, A.R. Marrero-Gonzalez, M.N. Stevens, A.V. Drawdy, A.E. Kejner

  • Outcomes of Tinnitus Interventions: An Umbrella Review of Systematic Reviews with Meta-Analysis

    by Kaiwen Chen, Neil P. Monaghan, Shaun A. Nguyen, Warren B. Chun, John F. Mills, Emily Brennan, Ted A. Meyer

    Objectives: Tinnitus is a highly prevalent and challenging neurotologic condition affecting over 740 million individuals worldwide. Despite the growing number of studies, treatment approaches remain fragmented and inconsistent. This umbrella review aims to aggregate results from systematic review to comprehensively synthesize the available evidence. Methods: Following PRISMA guidelines, we systematically searched CINAHL, COCHRANE Library, PubMed, and Scopus through April 2025. Systematic reviews with meta-analyses of primary tinnitus interventions were included. Outcomes focused on validated measures of tinnitus severity, distress, loudness, and quality of life. Study quality was assessed using AMSTAR-2. Results: A total of 44 systematic reviews were included, covering 7 intervention domains. Cognitive behavioral therapy (CBT), hearing aids, tinnitus retraining therapy (TRT), and sound/music therapy consistently improved tinnitus-related outcomes (eg, THI reductions up to −14.50, P < .001). Cochlear implantation yielded the largest effects (eg, THI −29.97) but is reserved for patients with moderate-to-profound sensorineural hearing loss who are not adequately helped by hearing aids. Neuromodulation and acupuncture showed modest or inconsistent benefits with high heterogeneity. Conclusions: This umbrella review provides the current and comprehensive analysis of tinnitus treatments. CBT, hearing aids, TRT, and sound/music therapy show consistent benefit. Cochlear implantation offers the greatest effect in patients with moderate-to-profound hearing loss unresponsive to hearing aids. Other therapies show mixed evidence. These findings offer a much-needed evidence framework to guide treatment decisions and future research.


  • Open Access

    Special Issue on Skin Cancers of the Head and Neck

    by Kaiwen Chen, Shaun A. Nguyen, Kaitlyn A. Roberts, Warren B. Chun, Cherie-Ann O. Nathan

    In this Special Issue of Cancers, we bring together a collection of five studies that capture the rapidly evolving landscape of skin malignancies of the head and neck

  • Open Access

    Sex and survival in oropharyngeal squamous cell carcinoma: A systematic review and meta-analysis

    by W.B. Chun, E.S. Chernov, K. Chen, S.A. Nguyen, A.R. Marrero-Gonzalez, M.N. Stevens, A.V. Drawdy, A.E. Kejner


  • Open Access

    Management of Regional Lymph Nodes in Clinically Node-Negative Cutaneous Squamous Cell Carcinoma of the Head and Neck: A Systematic Review & Meta-Analysis

    by Kaitlyn A. Roberts, Kaiwen Chen, Benjamin M. Wahle, Shaun A. Nguyen, Michael G. Moore, Jessica A. Yesensky

    Background/Objectives: Head and neck cutaneous squamous cell carcinoma (HNcSCC) has the potential to metastasize to local lymph nodes, which can significantly impact prognosis. However, the optimal management of patients with clinically node-negative (cN0) disease remains unclear. Methods: We conducted a systematic review and meta-analysis following PRISMA guidelines. PubMed, Scopus, CINAHL, and Web of Science databases were searched from inception to 7 August 2025. Two parallel searches were conducted: one to capture management strategies and outcomes of cN0 patients with HNcSCC and one to capture occult nodal metastasis rates of the same population. Results: A total of 38 studies were included. Post-excision management strategies included observation, sentinel lymph node biopsy (SLNB), elective dissection (ED), and elective nodal irradiation. The pooled rate of occult lymph node metastasis was 13.9% in 1673 HNcSCC tumors overall and 12.5% when limited to 977 high-risk tumors. Overall recurrence in the SLNB group (8.3%) was significantly lower than both the observation (16.9%, p < 0.0001) and ED (23.7%, p < 0.0001) groups. Additionally, overall mortality in the SLNB group (6.1%) was significantly lower than observation (29.9%, p < 0.0001) and ED (31.4%, p < 0.0001). Conclusions: We found that SLNB was associated with lower recurrence and mortality compared with observation and ED. While not assumed to be causative, our findings support the role of SLNB in diagnosing occult metastasis and staging disease in this population.


  • Appraisal of clinical practice guidelines for salivary gland cancer management utilizing AGREE II instrument

    by Kaiwen Chen, Young Lee, Jonathan P. Kuriakose, Najm S. Khan, Alvaro Moreira, Karthik Rajasekaran


  • ECG of the Month

    by Kaiwen Chen, Matthew Tanner, Justin D. Thomason

    "ECG of the Month" published on 12 May 2022 by American Veterinary Medical Association.

  • Cytomegalovirus events in high‐risk allogeneic hematopoietic‐cell transplantation patients who received letermovir prophylaxis

    by Kaiwen Chen, Esther Arbona‐Haddad, Matthew P. Cheng, Anne M. McDonnell, Mahasweta Gooptu, Jose L. Orejas, Kaitlyn Timblin, Emily Silverman, Rama Al‐Hamed, Robert J. Soiffer, et al.

    Letermovir is approved for the prevention of cytomegalovirus (CMV) reactivation and clinical disease in patients undergoing allogeneic hematopoietic‐cell transplantation (HCT). However, there is uncertainty about letermovir's ability to prevent clinical events during the period of prophylaxis as well as after the discontinuation of prophylaxis in the post‐transplant setting. We performed a retrospective cohort study in CMV‐seropositive allogeneic HCT recipients at high risk of CMV events, who received letermovir for primary prophylaxis from November 2017 through December 2019. We analyzed CMV outcomes for these patients during and after prophylaxis was discontinued. Patient outcomes were followed through June 2020. Sixty patients received letermovir for a median of 13 weeks (range, 1‐72 weeks). Thirteen (22%) patients had quantifiable CMV DNAemia (reactivation) during letermovir prophylaxis a median of 9 days (range, 1‐59 days) after starting letermovir. Five (8%) of these patients discontinued prophylaxis and received preemptive therapy (PET) with valganciclovir; eight (13%) continued letermovir as prophylaxis and CMV DNAemia resolved without PET. Thirteen patients (22%) had post‐prophylaxis CMV reactivation a median of 33 days (range, 14‐109 days) after letermovir discontinuation. In four (7%) of these patients, CMV DNAemia resolved without PET, and nine (15%) received PET. No patient developed CMV disease. Patients who developed CMV reactivation during prophylaxis did so shortly after initiation of letermovir, and most patients who developed CMV reactivation post‐prophylaxis did so within 60 days after discontinuation of letermovir. Letermovir prophylaxis has changed the presentation of CMV infection in high‐risk HCT patients.